SCHEMBL5466569

SCHEMBL5466569

Cc1ccc(N2CCN(C(=O)NCCCN3CCCCC3)CC2)c(C)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.52
DRD2 P14416 2/20 0.51
DRD3 P35462 2/20 0.51
DRD4 P21917 1/20 0.51
GSK3B P49841 2/20 0.51
HTR1A P08908 1/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
POLB P06746 3/20 0.49
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ADRA1D P25100 1/20 0.49
ADRA1A P35348 1/20 0.49
ADRA1B P35368 1/20 0.49
HTT P42858 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14372241 0.84 DRD2 (0.62) DRD2DRD3DRD4POLBADRA1D
SCHEMBL5476243 0.82 DRD3 (0.61) DRD2DRD3HTR1A
SCHEMBL5468391 0.81 DRD2 (0.56) MAPTDRD2DRD3DRD4GSK3B
SCHEMBL5477260 0.78 DRD2 (0.58) DRD2DRD3HTR1AHTR1DSMN1; SMN2
SCHEMBL5457584 0.78 DRD2 (0.66) DRD2DRD3DRD4ADRA1A
SCHEMBL5470996 0.77 DRD2 (0.57) MAPTDRD2DRD3DRD4HTR1A
SCHEMBL5457389 0.77 DRD2 (0.73) DRD2DRD3DRD4ADRA1DADRA1A
SCHEMBL5464156 0.76 ALDH1A1 (0.70) DRD2DRD3POLBSMN1; SMN2ALDH1A1
SCHEMBL7601660 0.75 ADRA1D (0.56) MAPTDRD2DRD3DRD4GSK3B
SCHEMBL5468384 0.74 DRD2 (0.62) MAPTDRD2DRD3DRD4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression HRH3, HRH1, HRH4 MAPT 2563/4885DRD2 34/4885DRD3 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.